Abstract

Purpose

To evaluate the efficacy and safety of radiofrequency ablation for low-risk papillary thyroid microcarcinoma (PTMC) in patients aged 55 years or older.

Methods

This retrospective study included 95 patients aged 55 years or older who underwent radiofrequency ablation (RFA) for PTMCs between June 2014 and January 2019. Incidence and duration of postoperative complications were recorded and evaluated. Tumor volume and volume reduction rate (VRR) changes were calculated. Patients were also closely monitored for tumor recurrence, regrowth, and lymph node metastasis.

Results

All nodules were completely ablated. The mean initial volume of the ablated thyroid nodules was 107.27 ± 99.10 mm³, and the volume decreased significantly during the follow-up time. The VRR in 1st, 3rd, 6th, 12th, 18th, 24th and 36th month were −591.64 ± 623.65%, −170.89 ± 319.51%, 9.74 ± 128.43%, 77.99 ± 45.26%, 99.35 ± 3.61%, 99.45 ± 3.05% and 99.78 ± 1.54%, respectively. No patient had any life-threatening complications. One patient had lymph node metastasis and one had a recurrence; both underwent a second radiofrequency ablation treatment and achieved satisfactory treatment results.

Conclusions

Our study suggests that radiofrequency ablation is a safe and effective option for low-risk PTMC in patients aged 55 years or older who are at a high risk of general anesthesia and postoperative complications or those who refuse surgery.

中文翻译：

---

超声引导下射频消融治疗55岁以上低危甲状腺乳头状甲状腺癌的疗效和安全性：一项回顾性研究

摘要

目的

评估射频消融术对55岁或以上低危型甲状腺乳头状微癌（PTMC）的疗效和安全性。

方法

这项回顾性研究纳入了2014年6月至2019年1月之间接受PTMC射频消融（RFA）的95岁，年龄在55岁以上的患者。记录并评估了术后并发症的发生率和持续时间。计算肿瘤体积和体积减少率（VRR）变化。还密切监测患者的肿瘤复发，再生长和淋巴结转移情况。

结果

所有结节均被完全消融。消融甲状腺结节的平均初始体积为107.27±99.10 mm ³，并且在随访期间体积显着减少。第1、3、6、12、18、24和36个月的VRR为−591.64±623.65％，− 170.89±319.51％，9.74±128.43％，77.99±45.26％，99.35±3.61％，99.45±3.05％和分别为99.78±1.54％。没有患者有任何危及生命的并发症。1例患者发生淋巴结转移，1例复发。均接受了第二次射频消融治疗，取得了满意的治疗效果。

结论

我们的研究表明，对于高危全身麻醉和术后并发症高风险或拒绝手术的55岁或55岁以上患者，射频消融是低风险PTMC的安全有效选择。